Scientific Professionals Launches the Scientific Academy

  Scientific Professionals, part of the Clinical Professionals Group, are proud to announce the launch of the Scientific Academy in collaboration with Barts Health Pharmaceuticals. Scientific Professionals will be assessing and fully funding some of the UK’s brightest scientific graduates to attend BHPs’ already established Aseptic Techniques and Operations (AT&O) course. With the aim of

Continue Reading

New Disease Compounds Research Library Launched by the Medical Research Council

The Medical Research Council (MRC) has teamed up with six pharmaceutical companies to create a disease compounds library for academic researchers around the world. The library is the latest product of the MRC’s Industry Asset Sharing Initiative, which comprises of 47 deprioritised compounds contributed by AstraZeneca, GlaxoSmithKline, Janssen, Pfizer, Takeda and UCB. Both pre-clinical and

Continue Reading

Chemists make key advancements to simplify drug design and production

Researchers at Rice University, the University of Texas Southwestern Medical Center and Brigham Young University have discovered a one-step solution to make nitrogen-laden molecular precursors for the preparation of drugs and other bioactive molecules. Research announced this month in Science will simplify the process and cut the cost of creating key nitrogen-containing functional groups for

Continue Reading

Clinical Professionals Group Shortlisted for APSCo 2016 Award

We are delighted to announce that The Clinical Professionals Group are shortlisted for the APSCo “Recruitment Company with the Most Sustainable Growth” award. The award recognises companies that have shown consistent growth over the past 5 years whilst demonstrating the professional values and exceptional performance associated with APSCo membership. We were required to demonstrate how

Continue Reading

Pfizer Publish New Analysis Showing Long Term Therapy Slowed Progression of Rare Neurodegenerative Disease

Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the

Continue Reading

Trial for Sandoz biosimilar hailed as ‘landmark’

Clinical data gathered for Sandoz’s biosimilar Etanercept (derived from Amgen and Pfizer’s Enbrel) was based from a “landmark” trial design in psoriasis in which over 500 patients switched from the original drug to the biosimilar. The data from the EGALITY trial showed the Novartis unit’s biosimilar, filed in the US and EU, met primary endpoint

Continue Reading